慢性肾脏病合并房颤抗凝治疗的获益与风险解读
本文综述慢性肾脏病(CKD)合并房颤患者抗凝治疗的获益与风险。普通人群随机对照试验显示华法林和直接口服抗凝药获益大于出血风险,但肌酐清除率低于25-30 ml/min者缺乏随机对照试验数据。文章汇总观察性及药代动力学研究,为CKD 3、4、5期及透析患者临床决策提供参考。
要点
- CKD患者房颤、缺血性卒中及出血风险均升高。
- 肌酐清除率低于25-30 ml/min者缺乏抗凝随机对照试验证据。
- 现有实践依据观察性研究和药代动力学研究等不完善文献。
核心结论
- CKD合并房颤患者抗凝治疗的获益与风险平衡尚不明确,需综合不完善文献个体化决策。
研究设计与样本
- 本文为当代文献综述,覆盖CKD 3、4、5期及透析合并房颤患者抗凝治疗获益与风险的文献。
主要发现
- 普通人群随机对照试验证实华法林和直接口服抗凝药获益大于出血风险。
- 肌酐清除率低于25-30 ml/min的患者缺乏随机对照试验数据。
- CKD患者房颤、缺血性卒中和出血风险均升高。
临床怎么用
- 医生可借助本文解读复杂文献,将抗凝证据应用于CKD合并房颤患者的临床照护。
局限性
- CKD 3-5期及透析患者缺乏随机对照试验数据,证据来自观察性和药代动力学研究等不完善文献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with CKD represent a vulnerable population where the risks of atrial fibrillation, ischemic stroke, and bleeding are all heightened. Although large randomized, controlled trials in the general population clearly demonstrate that the benefits of warfarin and direct-acting oral anticoagulants outweigh the risks of bleeding, no such studies have been conducted in patients when their creatinine clearance falls below 25-30 ml/min. Without randomized, controlled trial data, the role of anticoagulation in patients with CKD with atrial fibrillation remains unclear and our practice is informed by a growing body of imperfect literature such as observational and pharmacokinetic studies. This article aims to present a contemporary literature review of the benefits versus harms of anticoagulation in atrial fibrillation for patients with CKD stages 3, 4, 5, and 5 on dialysis. Although unanswered questions and areas of clinical equipoise remain, this piece serves to assist physicians in interpreting the complex body of literature and applying it to their clinical care.
引用
- Garlo KG, Steele DJR, Nigwekar SU, et al. Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2018. PMID: 30593489. doi:10.2215/CJN.06430518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。